ImmunoOncology (I-O) Archives - MediPaper Medical Communications Ltd

ImmunoOncology (I-O) is a fast developing field in which drugs stimulate the patient’s immune system to fight cancer. I-O include immune-checkpoint inhibitors, vaccines, and DAR-T, CAR-T cell & BiTE immunotherapies. Read our I-O blog and learn more about this fast-evolving field of medicine.

Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer

9th March 2019/0 Comments/in Breast Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals /by News Feed

On 8 March 2019, the FDA granted accelerated approval to atezolizumab (Tecentriq®, Genentech/Roche) in combination with albumin-bound paclitaxel (nab-paclitaxel) for the treatment of adult unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) patients with programmed death 1 ligand (PD-L1) stained tumour-infiltrating immune cells (IC) of any intensity covering ≥1% of the tumour area, as determined by the VENTANA PD-L1 (SP142) Assay companion diagnostic (CDx).

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 09-Mar-2019

9th March 2019/17 Comments/in AE Management, Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, ImmunoOncology, Immunotherapy, irAE Management, Lung Cancer, Melanoma & Skin Cancer, Oncology /by News Feed

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

Immunoncology I-O drugs and immunotherapy for renal cancer RCC

Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

5th March 2019/Enter your password to view comments./in -, Genitourinary Cancer, ImmunoOncology, Immunotherapy, Oncology, Translational Research /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Pembrolizumab FDA approved for adjuvant treatment of melanoma

16th February 2019/0 Comments/in ImmunoOncology, Immunotherapy, Melanoma & Skin Cancer, Oncology, Surgery, US FDA Onc\Haem Approvals /by News Feed

On 15 February 2019, the FDA approved pembrolizumab (Keytruda®, Merck) for the adjuvant treatment of melanoma patients with lymph node involvement following complete resection.

Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

14th January 2019/0 Comments/in ImmunoOncology, Immunotherapy, Melanoma & Skin Cancer, Oncology, US FDA Onc\Haem Approvals /by Stijn van den Borne, MSc

On 19 December 2018, pembrolizumab (Keytruda®, Merck) received accelerated approval by the FDA for the treatment of recurrent locally advanced or metastatic (R/M) Merkel cell carcinoma (MCC) in adult and paediatric patients.

Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

11th December 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Targeted Therapies, US FDA Onc\Haem Approvals /by News Feed

On 6 December 2018, the FDA approved atezolizumab (Tecentriq®, Roche/Genentech) plus bevacizumab and chemotherapy with paclitaxel and carboplatin for the frontline treatment of metastatic non-squamous non-small cell lung cancer (NSq NSCLC) patients not harbouring any EGFR or ALK genomic tumour aberrations.

Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

19th November 2018/1 Comment/in Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, US FDA Onc\Haem Approvals /by News Feed

On 9 November 2018, the FDA granted accelerated approval to pembrolizumab (Keytruda®, Merck) for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.

ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

3rd November 2018/1 Comment/in Conferences, ESMO 2018 Annual Meeting, Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, Targeted Therapies, Translational Research /by Stijn van den Borne, MSc

Whereas this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2018) boasted two Phase III studies and four Phase II studies with notable results in hepatocellular carcinoma (HCC), the trend did not continue to the European Society for Medical Oncology Conference (ESMO 2018), held in Münich, Germany between October 19-23, 2018. The focus for this years ESMO was mostly on biliary-tract cancers (BTC). Welcome to the hepatobiliary track of ESMO 2018.

Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

1st November 2018/1 Comment/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, US FDA Onc\Haem Approvals /by News Feed

On October 30th 2018, the FDA approved the use of programmed death 1 (PD-1) inhibitor pembrolizumab (Keytruda®, Merck) in combination with carboplatin plus paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).

Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

Management of Immune-Mediated Hepatitis: a Case Report

31st October 2018/Enter your password to view comments./in China, Genitourinary Cancer, ImmunoOncology, Immunotherapy, irAE Management, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

15th October 2018/0 Comments/in Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Medical News Asia, Oncology, Targeted Therapies /by News Feed

SUZHOU, China, Oct. 14, 2018 /PRNewswire/ — The combination therapy of novel programmed death 1 (PD-1) antibody IBI308 (sintilimab, Innovent Biologics) with biosimilar bevacizumab antibody IBI305 (Innovent Biologics) has received the investigational new drug (IND) application for clinical development approval by the National Medical Products Administration (NMPA, formerly known as CFDA) in China.

IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

11th October 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by News Feed

Atezolizumab (Tecentriq®, Roche/Genentech) plus standard chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (SCLC) was associated with a significantly longer overall survival (OS) and progression-free survival (PFS) when compared with chemotherapy alone.

Pembrolizumab plus chemotherapy effective in squamous NSCLC

Pembrolizumab plus chemotherapy effective in squamous NSCLC

8th October 2018/2 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by News Feed

Pembrolizumab (Keytruda®, Merck) in combination with chemotherapy was associated with longer overall survival (OS) and progression-free survival (PFS) when compared to placebo plus chemotherapy in patients with untreated metastatic squamous cell non-small cell lung cancer (NSCLC).

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

7th October 2018/0 Comments/in Chemotherapy, Gynaecological Cancer, ImmunoOncology, Oncology /by News Feed

Adding ipilimumab (IPI [Yervoy®, Bristol-Myers Squibb]) to nivolumab (NIVO [Opdivo®, Bristol-Myers Squibb]) induction followed by maintenance with single-agent NIVO had a superior objective tumour response rate and progression-free survival (PFS) when compared to NIVO alone in patients with persistent or recurrent epithelial ovarian cancer.

CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

5th October 2018/0 Comments/in Haematology, ImmunoOncology, Immunotherapy, Medical News Asia, Oncology /by News Feed

TOKYO and BASKING RIDGE, N.J., October 3, 2018 /PRNewswire/ — The Japan Ministry of Health, Labour and Welfare (MHLW) granted the Orphan Drug designation to axicabtagene ciloleucel (KTE-C19, Daiichi Sankyo) for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL), and transformed follicular lymphoma (TFL), which are all aggressive forms of non-Hodgkin lymphoma (NHL).

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

3rd October 2018/1 Comment/in ImmunoOncology, Immunotherapy, Melanoma & Skin Cancer, Oncology, US FDA Onc\Haem Approvals /by News Feed

On September 28, 2018, the FDA approved programmed death 1 (PD-1) immune-checkpoint inhibitor cemiplimab-rwlc (Libtayo®, Regeneron) for use in patients with metastatic cutaneous squamous cell carcinoma (CSCC) and patients with locally advanced CSCC unamenable for curative surgery or curative radiation.

JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

2nd October 2018/0 Comments/in ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, WCLC 2018 /by News Feed

Avelumab (Bavencio®, Merck KGaA) does not improve the overall survival (OS) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-doublet chemotherapy, as resulted from the JAVELIN Lung 200 study (NCT02395172). The safety profile favoured avelumab over docetaxel.

Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

25th September 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, WCLC 2018 /by News Feed

An interim analysis of the Phase III IMpower132 study showed that atezolizumab (Tecentriq®, Roche/Genentech) plus platinum-based chemotherapy (cisplatin or carboplatin) with pemetrexed improves the median progression-free survival (PFS) in treatment-naïve patients with non-squamous non-small cell lung cancer (NSCLC). The median PFS for atezolizumab plus pemetrexed and a platinum salt was 7.6 months vs 5.2 months with chemotherapy alone (HR=0.60, 95% CI: 0.49-0.72; p<0.0001).

immuno-oncology I-O treatment for the irAE Rash

©MediPaper Medical Communications Ltd

ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

21st September 2018/Enter your password to view comments./in ImmunoOncology, Immunotherapy, irAE Management, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

19th September 2018/Enter your password to view comments./in Head and Neck Cancer, ImmunoOncology, Immunotherapy, irAE Management, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Camrelizumab anti-PD-1 with or without Chemotherapy for NPC

Camrelizumab anti-PD-1 with or without chemotherapy for NPC

18th September 2018/0 Comments/in Chemotherapy, China, Head and Neck Cancer, ImmunoOncology, Immunotherapy, Oncology /by News Feed

Camrelizumab (SHR-1210, Hengrui Medicine), a novel programmed death 1 (PD-1) inhibitor, plus gemcitabine and cisplatin showed a manageable toxicity profile with promising, preliminary anti-tumour activity in treatment-naïve Chinese nasopharyngeal carcinoma (NPC) patients. Larger, randomised controlled trials may provide further insight into the role of anti-PD1 for NPC, wrote the authors in the Lancet Oncology.

Adrian TSE HKIOC irAE pneumonitis lung immunotherapy-induced pneumonitis I-O Immuno-Oncology cannonball metastases cancer

©MediPaper Medical Communications Ltd

I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis

14th September 2018/Enter your password to view comments./in ImmunoOncology, Immunotherapy, irAE Management, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

CAR-TCR Summit 2018 Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

© Royaltystockphoto / 123RF Stock Photo

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

9th September 2018/0 Comments/in China, ImmunoOncology, Immunotherapy, Medical News Asia, Oncology /by News Feed

CARsgen Therapeutics, a Shanghai-based clinical-stage immune-oncology company committed to developing Chimeric Antigen Receptor T (CAR-T) cell therapies for cancer, presented preliminary data of their first-in-class CAR-Claudin18.2 T-cell clinical trial in pancreatic and gastric cancer patients during the 2018 CAR-TCR Summit in Boston.

Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

Plasma TMB predicts response to atezolizumab in NSCLC patients

31st August 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Pathology, Translational Research /by News Feed

A high tumour mutational burden in the plasma (bTMB) is a clinically actionable biomarker for atezolizumab (Tencentriq®, Roche) treatment in patients who failed 1st-line platinum-based therapy for advanced non-small cell lung cancer (NSCLC).

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

© luchschen / 123RF Stock Photo

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22nd August 2018/0 Comments/in Breast Cancer, Genitourinary Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Medical News Asia, Melanoma & Skin Cancer, Oncology, Oncology News, Translational Research /by News Feed

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

Pembrolizumab and atezolizumab USPIs updated by FDA

21st August 2018/1 Comment/in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals /by News Feed

On the 16th of August, 2018, the FDA updated the prescribing information for pembrolizumab (Keytruda®, Merck) and atezolizumab (Tecentriq®, Roche/Genentech) and added the requirement for the use of an FDA-approved companion diagnostic test (CDx) to determine PD-L1 levels in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

21st August 2018/0 Comments/in ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, US FDA Onc\Haem Approvals /by News Feed

On the 16th of August 2018, the FDA granted accelerated approval to nivolumab (Opdivo®, Bristol-Myers Squibb) for use in patients with metastatic small cell lung cancer (SCLC) who progressed after two lines of therapy, including one line of platinum-based chemotherapy.

Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

21st August 2018/2 Comments/in ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, US FDA Onc\Haem Approvals /by News Feed

On 20th of August 2018, the FDA granted regular approval for pembrolizumab (Keytruda®, Merck) plus pemetrexed and a platinum salt in the first-line treatment of patients with metastatic, non-squamous non-small cell lung cancer (NSCLC), not harbouring any EGFR or ALK genomic tumour aberrations.

CheckMate 032 Nivolumab ipilimumab metastatic esophagogastric cancer

CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

18th August 2018/0 Comments/in Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, Translational Research /by News Feed

Immunotherapy with either nivolumab (Opdivo®, Bristol-Myers Squibb) alone or the combination nivolumab plus ipilimumab (Yervoy®, Bristol-Myers Squibb) in patients with chemotherapy-refractory esophagogastric cancer leads to durable responses and encouraging long-term overall survival with a manageable safety profile, concluded the investigators of the CheckMate 032 study.

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

26th July 2018/0 Comments/in ImmunoOncology, Immunotherapy, Melanoma & Skin Cancer, Oncology /by News Feed

Programmed death 1 (PD-1) inhibition with the novel human anti-PD1 monoclonal antibody cemiplimab (REGN2810, Regeneron and Sanofi) in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma (CSCC) resulted in a response in approximately half of the patients.

EBV pembrolizumab gastric cancer - MSI-H pembrolizumab gastric cancer - CPS pembrolizumab gastric cancer - MSI, EBV, CPS predict pembrolizumab outcome in gastric cancer

© abhijith3747/123RF

EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer

16th July 2018/0 Comments/in Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, Translational Research /by News Feed

Metastatic gastric cancer (mGC) patients with microsatellite instability-high (MSI-H) or Epstein-Barr virus (EBV)-positive tumours, or those with a positive (≥1%) combined positive score (CPS) respond best to pembrolizumab PD-1 immunotherapy.

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC

11th July 2018/2 Comments/in Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals /by News Feed

On July 10th, the FDA granted accelerated approval to ipilimumab (Yervoy©, Bristol-Myers Squibb) for use in combination with nivolumab (Opdivo©) for the treatment of adult and paediatric patients ≥12 years of age with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower

©eraxion / 123RF Stock Photo

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

25th June 2018/5 Comments/in ASCO 2018 Annual Meeting, Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Targeted Therapies /by Anne John Michael

Non-small cell lung cancer (NSCLC): a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with single-agent immunotherapy (I-O) and combinations of I-O with chemotherapy (CTx), including the CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Furthermore, important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567).

FDA has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy. More Information. June 19, 2018

FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

19th June 2018/1 Comment/in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Oncology, Translational Research, US FDA Onc\Haem Approvals /by News Feed

On June 19, the FDA limited the use of atezolizumab and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer patients ineligible for cisplatin-containing therapy.

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

14th June 2018/1 Comment/in Haematology, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals /by News Feed

On June 13, 2018, the US FDA has granted accelerated approval to pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for the treatment of adult and pediatric patients with primary mediastinal large B-cell lymphoma (PMBCL), relapsed after two or more prior lines of prior therapy.

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1

13th June 2018/0 Comments/in Gynaecological Cancer, ImmunoOncology, Immunotherapy, Oncology, Translational Research, US FDA Onc\Haem Approvals /by News Feed

On June 12, 2018 the FDA approved pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for patients with chemotherapy-refractory recurrent or metastatic (r/m) cervical cancer and with a combined positive score (CPS)≥1 PD-L1 level expression.

ASCO18 ASCO 2018 HCC hepatocellular carcinoma liver cancer pembrolizumab KEYTRUDA atezolizumab TECENTRIQ PD-1 PD-L1 immunecheckpoint immunotherapy ramucirumab cabozantinib KEYNOTE-224 SCRUM-Japan GI-SCREEN CELESTIAL REACH-2

© krishnacreations / 123RF Stock Photo

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

10th June 2018/3 Comments/in ASCO 2018 Annual Meeting, Chemotherapy, Conferences, Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, Targeted Therapies, Translational Research /by Anne John Michael

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

10th May 2018/3 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

First-line atezolizumab plus bevacizumab, carboplatin and paclitaxel improves PFS in patients with non-squamous NSCLC. Two presentations on the IMPower150 study by Martin Reck (ELCC 2018) and Mark Socinski (AACR 2018) discussed the frontline addition of atezolizumab to bevacizumab and chemotherapy in different lung cancer subgroups (NCT02366143).

US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018

2nd May 2018/5 Comments/in Haematology, ImmunoOncology, Immunotherapy, Oncology /by Stijn van den Borne, MSc

The two CAR-T cell immunotherapies axicabtagene ciloleucel (Yescarta®) and tisagenlecleucel (Kymriah®) and the BiTE blinatumomab (Blincyto®) have in common that they target CD19 on the cancer cells. Do you know all the US FDA approved CAR-T and BiTE immunotherapies?

AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826

Hywards / 123RF Stock Photo

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

21st April 2018/6 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

AACR 2018: First-line nivolumab–ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

krishnacreations / 123RF Stock Photo

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

19th April 2018/4 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

AACR 2018: Frontline pembrolizumab plus chemotherapy in NSCLC reduces the risk of death by more than 50%. The Phase III KEYNOTE-189 trial combined pembrolizumab (Keytruda®) plus standard of care platinum-based chemotherapy in non-squamous non–small cell lung cancer (NSCLC) without EGFR or ALK genetic aberrations (NCT0278680)

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC

16th April 2018/1 Comment/in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals /by News Feed

The FDA granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.

Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

10th April 2018/1 Comment/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

Pembrolizumab (Keytruda®) as single-agent immunotherapy in the frontline setting of any histology NSCLC with a PD-L1 expression ≥1% was associated with improved overall survival (OS) when compared to platinum-doublet chemotherapy in the KEYNOTE-042.

Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

I-O in Special Populations: Diabetes and Concomitant Steroids

6th April 2018/Enter your password to view comments./in AE Management, ImmunoOncology, Immunotherapy, irAE Management, Oncology, Radiology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

31st March 2018/0 Comments/in Head and Neck Cancer, ImmunoOncology, Immunotherapy, Oncology /by Stijn van den Borne, MSc

Nivolumab (OpdivoⓇ) immunotherapy is active in nasopharyngeal carcinoma (NPC). A study published in JCO by Brigette Ma (CUHK) and a team of researchers from Hong Kong, Singapore, and the US showed promising results with nivolumab in NPC. Read more about immunotherapy in NPC.

©aquir / 123RF Stock Photo

FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

29th March 2018/0 Comments/in Haematology, ImmunoOncology, Immunotherapy, US FDA Onc\Haem Approvals /by News Feed

FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and paediatric patients with B-cell precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. More Information.

Making sense of immunotherapy in NSCLC

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

26th March 2018/5 Comments/in Guidelines, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by Stijn van den Borne, MSc

The expansion of therapeutic options with immunotherapies will reflect a dramatic change in the guidelines for lung cancer, where immunotherapies mostly compete with the use of chemotherapeutic agents. A brief communication on immunotherapies for NSCLC.

us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

Pembrolizumab approved for advanced gastric cancer

22nd September 2017/0 Comments/in Chemotherapy, Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Translational Research, US FDA Onc\Haem Approvals /by Stijn van den Borne, MSc

On September 22, 2017, the FDA granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for use in patients with locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for PD-L1 as determined by an FDA-approved companion diagnostic (CDx) and progressing after ≥2 prior systemic therapies, including a fluoropyrimidine– and platinum-containing regimen, and, when appropriate, HER2–targeted therapy.

us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

Nivolumab approved for sorafenib-refractory HCC

22nd September 2017/in Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Targeted Therapies, US FDA Onc\Haem Approvals /by Stijn van den Borne, MSc

On September 22, 2017, the Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. Approval was based on a 154-patient subgroup of CHECKMATE-040 (NCT 01658878), a multicenter, open-label trial conducted in patients with HCC and […]

Nivolumab Renal Cell Cancer Symposium Highlight

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

19th September 2017/Enter your password to view comments./in AE Management, Genitourinary Cancer, Head and Neck Cancer, ImmunoOncology, Immunotherapy, irAE Management, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

2017 CICS immunooncology annual meeting oncology medical writer medipaper medical communications

Interested in Attending an Immunooncology Conference?

21st June 2017/0 Comments/in Conferences, ImmunoOncology, Oncology, Translational Research /by Stijn van den Borne, MSc

The CICS Annual Conference on Immuno Oncology is offering the most significant advances in the world of oncology. The goal of the meeting is to convey the clinical and translational advances in various areas of cancer immunology to medical oncologists, medical students, and other health professionals.

PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

26th October 2016/Enter your password to view comments./in Gastrointestinal Cancer, Genitourinary Cancer, Haematology, Head and Neck Cancer, ImmunoOncology, Lung Cancer, Melanoma & Skin Cancer, Pathology, Translational Research /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Biomarkers Ipilimumab Treatment MediPaper Medical Communications

Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

24th October 2016/4 Comments/in ImmunoOncology, Oncology, Pathology, Translational Research /by Stijn van den Borne, MSc

The number of different types of T-helper cells (Th) and cytotoxic T cells (CD8) may predict response to ipilimumab in several malignancies. This was concluded by Dr Juan Pablo Márquez Manríquez who presented the study at the ESMO conference on behalf of the investigators of the Sonora Cancer Research Center (CICS) in Mexico and the United States (U.S.).

ESMO 2016 ipilimumab data medipaper medical communications

ESMO16 Ipilimumab data – Download the PPT

11th October 2016/Enter your password to view comments./in Conferences, ImmunoOncology, Melanoma & Skin Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

ESMO 2016 pembrolizumab data medipaper medical communications

ESMO16 Pembrolizumab data – Download the PPT

10th October 2016/Enter your password to view comments./in Conferences, Head and Neck Cancer, ImmunoOncology, Lung Cancer, Melanoma & Skin Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT

10th October 2016/Enter your password to view comments./in Conferences, Gastrointestinal Cancer, Genitourinary Cancer, ImmunoOncology, Lung Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

ESMO 2016 atezolizumab data medipaper medical communications

ESMO16 Atezolizumab data – Download the PPT

9th October 2016/Enter your password to view comments./in Conferences, Genitourinary Cancer, ImmunoOncology, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

ESMO 2016 nivolumab data medipaper medical communications

ESMO16 Nivolumab data – Download the PPT

9th October 2016/Enter your password to view comments./in Conferences, Genitourinary Cancer, Haematology, ImmunoOncology, Melanoma & Skin Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

IMM-101 plus gemcitabine-medipaper medical communications BW

IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer

25th September 2016/3 Comments/in Gastrointestinal Cancer, ImmunoOncology, Oncology /by Stijn van den Borne, MSc

A phase II proof-of-concept (POC) study investigating the safety and tolerability of immune modulator IMM-101 plus gemcitabine vs. single agent gemcitabine in advanced pancreatic ductal adenocarcinoma (PDAC) showed significant improved progression-free survival (PFS) and overall survival (OS) in metastatic patients receiving the combination treatment.

ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

ASCO16 Avelumab, Durvalumab, and Tremelimumab

3rd June 2016/Enter your password to view comments./in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Melanoma & Skin Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

asco 2016 atezolizumab data

ASCO16 Atezolizumab (Tecentriq©) Data

2nd June 2016/Enter your password to view comments./in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

ASCO2016 ipilimumab data - MediPaper Medical Communications

ASCO16 Ipilimumab (Yervoy©) Data

31st May 2016/Enter your password to view comments./in ImmunoOncology, Immunotherapy, Melanoma & Skin Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

29th May 2016/Enter your password to view comments./in Cardiovascular, ImmunoOncology, Immunotherapy, Lung Cancer, Melanoma & Skin Cancer /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

asco 2016 pembrolizumab medipaper medical communications

ASCO16 Pembrolizumab (Keytruda©) Data

29th May 2016/Enter your password to view comments./in ImmunoOncology, Immunotherapy, Lung Cancer, Melanoma & Skin Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Therapeutic Areas